Investigation of Antipsoriatic Effects of UVB-induced Synthesis of 1alpha, 25-Dihydroxyvitamin D3 (1alpha, 25(OH)2D3, Calcitriol)in Keratinocytes of Psoriatic Skin, Using Cytochrom-P(CYP)Inhibitor Ketokonazol

Phase 2UnknownNCT00678756

Technische Universität Dresden12 enrolled

Overview

Exploration of antipsoriatic effects of UVB-therapy +/- CYP-inhibitor Ketokonazol on affected psoriatic skin

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Psoriasis Vulgaris

Interventions

Ketokonazol 2% creamDRUG

twice a day at 2 times,2 out of 5 areas have to be treated for 4 weeks/7 days a week

UVB-radiation 311nmRADIATION

3 out of 5 areas are radiated for 4 weeks every MO/DI/DO/FR starting MED orientated, intensified everytime 0,03 J/qcm

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * age: 18- 80 * diagnosis of psoriasis vulgaris (mild- middle) * no other current antipsoriatic therapy (systemic/topical) * at least 5 psoriatic areas of 5x5 cm Exclusion Criteria: * pregnancy/nursing mothers * women in reproductive age without adequate contraception * severe and acute forms of psoriasis vulgaris * patients receiving systemic or topical antipsoroatic treatment in past 3 month * UV-therapy in past 3 month * patients having a positive anamnesis for squamous cell carcinoma, malignant melanoma, basalioma * epilepsy

Locations (1)

Department of Dermatology, Medical Faculty, TU Dresden

Dresden, Germany

Outcomes

Primary Outcomes

PASI, PGA

Time frame: 4 weeks

Secondary Outcomes

OCT/ultrasound- thickness of epidermis/ dermis

Time frame: 4 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.